Loading…
Employees: 33
Size Avalo Therapeutics (AVTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $372M, the 2917th largest of 3,117 United States companies the cockpit tracks. Shares closed at $6.93 on 6 Nov 2026.
Performance Over six months the shares fell 67.9%, against -19.1% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd lowest of 19 in its peer set.
Growth Revenue fell 86.6% over the last twelve months (peer median +3.0%); the operating margin is -154,844.1% (peer median -9.7%).
Capital Return on invested capital runs 151.4 points below its cost of capital (8.7% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $59,000 | $59,000 | $441,000 | $1.92M | $18.1M |
| Revenue growth | — | -87% | -77% | -89% | — |
| Gross profit | -$50,000 | -$285,000 | $638,000 | $640,000 | $14.6M |
| EBITDA | -$91.2M | -$72.6M | -$40.7M | -$23.3M | -$37.3M |
| Net income | -$100M | -$78.3M | -$35.1M | -$31.5M | -$41.7M |
| Free cash flow | -$68.3M | -$51.5M | -$49.1M | -$30.8M | -$26.8M |
| Capital expenditure | $0 | $0 | $0 | $158,000 | $95,000 |
| Total debt | $2.24M | $2.43M | $2.92M | $3.90M | $23.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AVTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -48.4% | -10.9% | lowest of 20 |
| 6-month return | -67.9% | -19.1% | 2nd lowest of 19 |
| Distance from 52-week high | -71.5% | -33.2% | 4th lowest of 21 |
| Revenue growth (TTM) | -86.6% | +3.0% | 2nd lowest of 18 |
| Operating margin | -154,844.1% | -9.7% | lowest of 17 |
| ROIC minus cost of capital | -151.4 pp | -8.8 pp | lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Avalo Therapeutics AVTX | United States | $372M | -68% | -87% | -154,844% | n/a | n/a | n/a |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $372M | n/a | +115% | 57% | 46.9× | n/a | n/a |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $372M | -17% | -24% | 3% | 1.1× | 4.2% | +3.1% |
| Chongqing Hifuture Information Technology 002168.SZ | China | $372M | -23% | +2% | -6% | 8.3× | 16.3% | -14.0% |
| Unichem Laboratories UNICHEMLAB.NS | India | $373M | +28% | +9% | 5% | 1.5× | n/a | n/a |
| Rezolute RZLT | United States | $375M | +21% | n/a | n/a | n/a | n/a | n/a |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $368M | -25% | +3% | 6% | 1.8× | 13.2% | +6.5% |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $376M | -21% | -26% | -15% | 2.0× | 9.0% | -11.3% |
| Hinova Pharmaceuticals 688302.SS | China | $366M | -24% | +251% | -195% | 22.0× | n/a | n/a |
| TRex Bio TRXB | United States | $364M | n/a | -100% | n/a | n/a | n/a | n/a |
| KYORIN Pharmaceutical 4569.T | Japan | $362M | -30% | -5% | 2% | 0.5× | 10.5% | +4.2% |
| JCR Pharmaceuticals 4552.T | Japan | $383M | -11% | +3% | -14% | 2.9× | n/a | n/a |
| MapLight Therapeutics MPLT | United States | $385M | -75% | n/a | n/a | n/a | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $386M | +10% | -12% | -140% | 70.7× | n/a | n/a |
| Lumosa Therapeutics 6535.TWO | Taiwan | $356M | -49% | -8% | -883% | 324.5× | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $392M | +15% | -1% | -13% | 5.2× | 23.2% | -15.7% |
| Heartseed 219A.T | Japan | $393M | +52% | +197% | 9% | 21.4× | 50.0% | +73.2% |
| Pharmicell 005690.KS | South Korea | $352M | -56% | +51% | 32% | 3.2× | -6.6% | +24.8% |
| SanBio 4592.T | Japan | $393M | -58% | n/a | n/a | n/a | n/a | n/a |
| Zota Health Care ZOTA.NS | India | $395M | -6% | +69% | -16% | 5.8× | n/a | n/a |
| Zhejiang East Asia Pharmaceutical 605177.SS | China | $348M | -3% | +3% | -17% | 3.1× | n/a | n/a |